The extended recovery ring stage survival assay provides superior prediction of patient clearance half life and increases throughput

Sage Z. Davis^{1,2§}, Puspendra P. Singh^{1§}, Katelyn M. Vendrely¹, Douglas A. Shoue¹, Lisa A. Checkley¹, Marina McDew-White³, Katrina A. Button-Simons¹, Zione Cassady¹, Mackenzie A.C. Sievert¹, Gabriel J. Foster¹, François H. Nosten^{4,5}, Timothy J.C. Anderson³, Michael T. Ferdig^{1*}

¹Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA

²Molecular, Cell, and Systems Biology Department, University of California Riverside, Riverside, CA, USA

³Texas Biomedical Research Institute, San Antonio, Texas, USA

⁴Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Mae Sot, Thailand

⁵Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research Building, University of Oxford Old Road Campus, Oxford, UK

*Corresponding author: Michael T. Ferdig (ferdig.1@nd.edu)

§These authors contributed equally to this work

Abstract

Background

Tracking and understanding artemisinin resistance is key for preventing global setbacks in malaria eradication efforts. The ring-stage survival assay (RSA) is the current gold standard for *in vitro* artemisinin resistance phenotyping. However, the RSA has several drawbacks: it is relatively low throughput, has high variance due to microscopy readout, and correlates poorly with the current benchmark for *in vivo* resistance, patient clearance half-life post-artemisinin treatment. Here a modified RSA is presented, the extended Recovery Ring-stage Survival Assay (eRRSA), using 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives, including parasite isolates with and without *kelch13* mutations.

Methods

P. falciparum cultures were synchronized with single layer Percoll during the schizont stage of the erythrocytic cycle. Cultures were left to reinvade to early ring-stage and parasitemia was quantified using flow cytometry. Cultures were diluted to 2% hematocrit and 0.5% parasitemia in a 96-well plate to start the assay, allowing for increased throughput and decreased variability between biological replicates. Parasites were treated with 700nM of dihydroartemisinin or an equivalent amount of dimethyl sulfoxide (DMSO) for 6 h, washed three times in drug-free media, and incubated for 66 or 114 h, when samples were collected and frozen for PCR amplification. A SYBR Green-based quantitative PCR method was used to quantify the fold-change between treated and untreated samples.

Results

15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives were assayed using the eRRSA. Due to the large number of pyknotic and dying parasites at 66 h post-exposure (72 h sample), parasites were grown for an additional cell cycle (114 h post-exposure, 120 h sample), which drastically improved correlation with patient clearance half-life compared to the 66 h post-exposure sample. A Spearman correlation of 0.8393 between fold change and patient clearance half-life was identified in these 15 isolates from Southeast Asia, which is the strongest correlation reported to date.

Conclusions

eRRSA drastically increases the efficiency and accuracy of *in vitro* artemisinin resistance phenotyping compared to the traditional RSA, which paves the way for extensive *in vitro* phenotyping of hundreds of artemisinin resistant parasites.

Keywords

Ring-stage survival assay, artemisinin resistance, *kelch13*

Background

Artemisinin (ART) resistance in malaria parasites is rapidly spreading through Southeast Asia, and recent reports indicate that resistance has reached Southern Asia (1-3). As artemisinin combination therapies (ACTs) are the recommended course of treatment for uncomplicated malaria by the World Health Organization (WHO), the rapid rise and spread of ART resistance raises concerns for the future of malaria treatment (4). The ability to track and understand ART resistance will be key in preventing global setbacks in malaria eradication efforts.

Measuring ART resistance is typically done *in vivo* using patient clearance half-life ($PC_{1/2}$), an assay that measures the linear decline of parasitemia in patients after drug treatment (5-7). Clinical ART resistance manifests as a delayed clearance of parasites from a patient's blood following treatment and is defined as a $PC_{1/2} \geq 5$ h (7). While the $PC_{1/2}$ provides a method to track ART resistance in the field, it has drawbacks, namely the requirement for patients to meet a strict inclusion criteria and agree to hospitalization to measure the $PC_{1/2}$ (8). To avoid this costly measure, *in vitro* measures of ART resistance have been developed. One of the most common *in vitro* measures of antimalarial drug resistance is the 50% inhibitory concentration (IC_{50}), which exposes parasites to serial dilutions of drug. However, delayed parasite clearance (as measured by $PC_{1/2}$) is not associated with a significant change in ART IC_{50} (8-10). This is because later parasite stages (such as trophozoites and schizonts) are highly susceptible to ART, but early ring-stage ART resistant parasites (0-3 h) are able to survive pulses of ART. Therefore, the ring-stage survival assay (RSA) was developed to distinguish ART resistant parasites *in vitro* and to have a better correlation with $PC_{1/2}$ data than artemisinin IC_{50} s (6, 8, 11).

76

77 The RSA has been the gold standard for measuring ART resistance *in vitro*, but it is a multi-step,
 78 laborious, and time-consuming assay that requires high volumes of very synchronized parasites.
 79 It is essential that the parasites are tightly synchronized in order to assay during the short window
 80 (0-3 h) that can differentiate ART resistant parasites from ART sensitive parasites. To do this,
 81 both a Percoll gradient and sorbitol are typically used (8), but several alterations have been
 82 attempted to increase the throughput of the assay such as using both sorbitol and magnet
 83 columns (12), using syringe filters to select for merozoites (13), and using a dual layer Percoll
 84 gradient, as has been done previously in other malaria assays (14, 15). Another major bottleneck
 85 and source of variability in the final readout of the RSA is counting viable malaria parasites by
 86 microscopy (8, 11, 14). To increase throughput, flow cytometry has become heavily utilized as
 87 an alternative to counting viable parasites by microscopy, removing hours of counting slides and
 88 human error (14, 16). However, staining of cells for flow cytometry to detect viable parasites is
 89 time sensitive and requires samples to be prepared immediately after the 66 h incubation, which
 90 can be time consuming and inconvenient (14).

91

92 Despite these advances in the protocol, the RSA is still far from being both high-throughput and
 93 highly reflective of $PC_{1/2}$. Recently, Mukherjee *et al.* used the RSA to measure the percent
 94 survival of 36 culture-adapted parasites, but only showed a correlation with $PC_{1/2}$ data of 0.377,
 95 suggesting there is still significant room for improvement (Spearman's Rho, internal calculations
 96 based off of supplemental data) (17).

97

Here a modified RSA is presented: the extended ring-stage recovery assay (eRRSA). This modified RSA protocol utilizes a simple single layer Percoll synchronization, flow cytometry to determine the stage and parasitemia for assay setup, a 96-well plate format for the assay, and a SYBR Green-based quantitative PCR (qPCR) method as the final readout. These modifications allow for a high-throughput *in vitro* experiment that better reproduces $PC_{1/2}$, allowing for improved segregation of resistant and sensitive parasites, as well as improved sorting of moderately resistant parasites. Further, efficiency improvements in the eRRSA allow for high throughput *in vitro* testing of ART resistance, accelerating our understanding of artemisinin resistance in the lab and providing a more accurate method to track the spread of resistance.

Methods

Parasite isolates

To evaluate the eRRSA methods, *Plasmodium falciparum* isolates with varying *kelch13* mutations and $PC_{1/2}$ were chosen. These isolates were derived from cloning by limiting dilution from patient samples. A total of 15 parasite isolates were chosen, 9 of which have *kelch13* mutations (including one C580Y mutant, the most common *kelch13* mutation found in Southeast Asia currently), and a $PC_{1/2}$ distribution between 1.67 and 9.24. All 15 parasite isolates were isolated from patients on the Thailand-Myanmar border between 2008 and 2012. 3D7 was used as a control for comparison to the 15 Southeast Asian isolates (Table 1) (18, 19).

119

120 **Parasite culture**

121 *P. falciparum* isolates were cultured using standard methods in human red blood cells (RBC)
 122 (Biochemed Services, Winchester, VA and Interstate Blood Bank, Memphis, TN) suspended in
 123 complete medium (CM) containing RPMI 1640 with L-glutamine (Gibco, Life Technologies.),
 124 50 mg/L hypoxanthine (Calbiochem, Sigma-Aldrich), 25 mM HEPES (Corning, VWR, 0.5%
 125 Albumax II (Gibco, Life Technologies.), 10 mg/L gentamicin (Gibco, Life Technologies) and
 126 0.225% NaHCO₃ (Corning, VWR) at 5% hematocrit. Cultures were grown separately in sealed
 127 flasks at 37°C under an atmosphere of 5% CO₂/5% O₂/90% N₂.

128

129 **Percoll synchronization**

130 Parasites were synchronized using a density gradient method as previously described with slight
 131 modifications (14, 15, 20). Briefly, 350ul of packed, infected erythrocytes at high schizogony
 132 (>50% schizonts) was suspended in 2ml of RPMI. Cultures were layered over a single 70%
 133 Percoll (Sigma-Aldrich) layer in 1x RPMI and 13.3% sorbitol in phosphate buffer saline (PBS)
 134 and centrifuged (1561xg for 10 min, no brake). The top layer of infected late stage schizonts was
 135 then removed and washed with 10 ml of RPMI twice. Cultures were then suspended in 2 ml of
 136 CM at 2% hematocrit and placed in culture flasks on a shaker in a 37 °C incubator for 4 h to
 137 allow for re-invasion.

138

139 **Flow cytometry**

4 h after Percoll synchronization (unless noted otherwise), samples were measured by flow cytometry as previously described with slight modifications to determine parasitemia (14, 16). Briefly, 80 µl of culture and an RBC control incubated for at least 8h at 5% hematocrit in CM were stained with SYBR Green I (SYBR) and SYTO 61 (SYTO) and measured on a guava easyCyte HT (Luminex Co.). Analysis was performed with guavaSoft version 3.3 (Luminex Co.). 50,000 events were recorded for both the RBC control and samples to determine relative parasitemias.

eRRSA setup

2 h post-cytometric quantitation (or 6 h after Percoll synchronization) samples whose stage composition was >70% rings as determined by flow cytometry were diluted to 2% hematocrit and 0.5% parasitemia (unless otherwise noted), and 200 µl of culture was aliquoted into 6 wells of a flat bottom 96-well plate. Each treated and untreated sample had three technical replicates: RBC controls were aliquoted into 2 wells at 2% hematocrit and 200 µl. 3 wells of parasites and 1 well of the RBC control were treated with 700nM dihydroartemisinin (DHA) (Sigma-Aldrich); an additional 3 wells of parasites and 1 well of RBC control was treated with an equivalent amount of dimethyl sulfoxide (DMSO) (ThermoFisher) as untreated controls. Parasites were incubated for 6 h, and then washed three times with 150 µl of RPMI to remove drug. Samples were then suspended in CM and placed back in the incubator. 66 h after drug removal, 20 µl of sample from each well was collected and frozen for qPCR amplification (72 h sample). Plates were then placed back in the incubator for another 48 h, after which 20 µl of sample was again collected and frozen for qPCR amplification (120 h sample).

qPCR Amplification

qPCR amplification was done as previously reported, with slight modifications (21). Ring stage samples were quantified at 72 and 120 h post-drug treatment. qPCR was performed using the Phusion Blood Direct PCR kit (ThermoFisher, cat # F547L), supplemented with 1x SYBR. 3 µl of culture was used in a 10 µl reaction and amplified using forward and reverse primers of the *Pfcr* gene. PCR amplification was measured using the fast mode of the ABI 7900HT, with a 20 s denaturation at 95 °C, followed by 30 cycles of 95 °C for 1 s, 62.3 °C for 30 s, and 65 °C for 15 s (Additional file 1). Cycle threshold (Ct) values were calculated using the ABI SDS 2.4.1. Fold change ($2^{\Delta Ct}$) was calculated by determining the average ΔCt for the three technical replicates for the untreated and treated samples by applying the following equation:

$$\text{Fold change} = 2^{(\text{average Ct of treated sample} - \text{average Ct of untreated sample})} \quad (\text{Eq. 1})$$

All statistics were performed and figures generated using GraphPad Prism version 8.2.1.

Results

Using a SYBR Green-based quantitative PCR method to quantify the fold-change between treated and untreated samples

Percent proliferation is the standard RSA measurement to determine whether a parasite is artemisinin resistant or sensitive. This is calculated by dividing the percent parasitemia in the treated (DHA) sample over the percent parasitemia in the untreated (DMSO) sample. Parasitemia is determined either by counting the number of viable and nonviable parasites using blood

smears and microscopy or by flow cytometry. Determining parasitemia with microscopy is cost effective and convenient but is also highly variable and time-consuming. Flow cytometry is typically very accurate; however, the process must be begun at upon reaching a timepoint, adding a substantial time investment at the point of sampling. To find another measurement of parasitemia that could be automated and have less variability, qPCR on parasite genomic DNA was tested. A standard curve of percent parasitemia (as measured by flow cytometry) shows excellent inverse correlation with Ct values as measured by qPCR (Figure 1). To quantify the difference between treated and untreated final RSA samples, fold change ($2^{\Delta Ct}$) was calculated according to equation 1.

RSA readout at 120 h provides superior differentiation between sensitive and resistant isolates

The standard RSA determines parasite viability at 72 h after drug treatment. However, a common problem in the final readout (using either microscopy, flow cytometry, or qPCR) is the difficulty in differentiating between pyknotic (nonviable) parasites and viable parasites 72 h after drug treatment. It is also difficult to measure viable parasitemia when it can be as low as 0.01% (or even 0% in some cases), especially when measuring ART sensitive parasites (22). To address these issues, the time to readout was extended by an additional intraerythrocytic development cycle (48 h). This extension was added to both allow parasites an additional expansion cycle, creating larger differences to distinguish resistant and sensitive isolates, and to allow erythrocytes to clear pyknotic parasites. This additional cycle provides a much greater separation between resistance and sensitive parasite isolates (Figure 2).

Assay set-up conditions have a substantial impact on RSA outcomes

The RSA is a growth assay targeted at a very narrow window of the parasite intraerythrocytic development cycle. In order to maximize the precision of the assay, the growth and the timing of the target window were carefully optimized. First, as it has been established that growth rates can vary based on parasitemia, the effect of varying starting parasitemias on RSA outcome was observed (23). RSA was performed on three parasite isolates (3D7, 1337, and 4673) at varying starting parasitemias as determined by a microscopist, and samples were collected at 72h and 120h (Additional file 2A and 2B, respectively). For the three parasite isolates tested, 3D7 was the ART sensitive control and 1337 and 4673 were two ART resistant parasite isolates as determined by their $PC_{1/2}$ values (1337 $PC_{1/2}$ = 7.84 and 4673 $PC_{1/2}$ = 5.34). The 0.25% starting parasitemia showed the most distinguishable phenotype between the ART sensitive 3D7 control and the two ART resistant isolates at 120 h (Additional file 2B). It was noted internally that determinations of parasitemia by microscopy varied widely and underestimated parasitemia compared to flow cytometry, likely due to the difficulty of correctly identifying new invasions. A comparison of RSA results from isolates set up at 0.25% parasitemia determined by microscopy and 0.5% parasitemia determined by flow cytometry showed no difference between the two (Additional file 3). As a result, in subsequent set-ups starting parasitemia was determined by flow cytometry and was normalized to 0.5% parasitemia.

A key factor in the RSA is applying the drug treatment in the tight 0-3 h window of the parasite life cycle that can differentiate ART resistant parasites from ART sensitive parasites. Therefore,

the time from Percoll synchronization to drug treatment was also varied to find the optimal time for drug treatment. The same three parasite isolates, (3D7, 1337, and 4673), were set up and treated with 700nM DHA 4 h, 6h, 8 h, or 10 h after Percoll synchronization and samples collected at 72 h and 120 h post-drug treatment (Additional file 2C and 2D, respectively). All parasites were set up at a starting parasitemia of 0.5% as measured by flow cytometry. The time that resulted in the most consistent and distinguishable phenotypes between the ART sensitive and resistant isolates was 6 h post-Percoll synchronization. Controlling these factors resulted in a more consistent and reproducible RSA phenotype.

Defining the eRRSA as an improvement over the standard RSA

Based on the previously described optimizations, the eRRSA is defined as a single layer Percoll synchronization, flow cytometry measurement of parasite parasitemia and stage prior to assay set-up, 700nM DHA treatment of 200ul of parasites at 2% hematocrit and 0.5% parasitemia in 96-well plates that are set up at 6 h post-Percoll synchronization, drug washed off 6 h after application, and samples for qPCR readout collected at 120 h post-drug treatment (Additional file 4). This protocol provides the most consistent and high-throughput results. These modifications made to the standard RSA are a new *in vitro* ART resistance phenotyping method: the Extended Ring-stage Recovery assay (eRRSA).

eRRSA correlates better with $PC_{1/2}$ than RSA

The RSA was introduced as an *in vitro* method that better captures the gold standard for *in vivo* ART resistance, $PC_{1/2}$, than the traditional IC_{50} . For a new assay to be relevant, it should perform

at least comparably to the existing standard. Therefore, the eRRSA was used to assay 15 isolates from Southeast Asia with varying known $PC_{1/2}$ and *kelch13* mutations collected between 2008 and 2012 (Table 1). We collected at least three biological replicates (each with three technical replicates) for each isolate and collected samples at 72 h and 120 h post-drug treatment and compared the viability of treated and untreated parasites at each stage.

The fold change data was then compared to $PC_{1/2}$: at the 72 h timepoint across 15 isolates, the eRRSA has a Spearman correlation coefficient of -0.6071 (Figure 3A). This is comparable to other RSA correlations in the field, showing that the improvements made to the RSA protocol do not significantly affect the outcome while increasing efficiency and ease of the assay (8, 17). The 120 h correlations, however, improved Spearman correlation between fold change and $PC_{1/2}$ to -0.8393 (Figure 3B).

Discussion

With the gradual spreading of artemisinin resistance throughout Southeast Asia, it is imperative that resistance can be accurately measured both in the field and in the lab. To date, the RSA has been the golden standard for *in vitro* measurement of artemisinin resistance. Despite this, there is a need for a more accurate, higher throughput *in vitro* measurement alternative to the current RSA to accelerate our understanding of artemisinin resistance. We have developed the eRRSA for this purpose and have shown that it can outperform the RSA in both accuracy and throughput.

270

271 A major bottleneck and source of variability in the RSA is the final readout to determine the ratio
 272 of viable parasites in the treated and untreated cultures. RSA uses microscopy or flow cytometry
 273 as the final readout, while the eRRSA uses qPCR. When using microscopy to compare viable
 274 and nonviable parasites, the presence of the ring-like structure of healthy, viable parasites are
 275 compared to the collapsed, nonviable parasites which can be highly subjective and time
 276 consuming, as shown by the original RSA paper which required two to three microscopists (14).
 277 Flow cytometry utilizes the DNA stain SYBR and the mitochondrial stain MitoTracker red to
 278 differentiate between viable and nonviable parasites. This eliminates the requirement of
 279 microscopists and drastically decreases the labor required to determine percent proliferation of
 280 parasites (14, 16). However, staining of cells for flow cytometry is time sensitive and must be
 281 done immediately following the end of the RSA (at 72 h), which can limit flexibility and
 282 lengthens an assay that already demands long hours. qPCR measure viable parasites solely by
 283 concentration of genomic material, comparing the efficiency of parasites to proliferate post-
 284 artemisinin perturbation. Here, the efficacy of qPCR is demonstrated as a readout for
 285 proliferation in a survival assay context. The use of qPCR allows for both smaller sample sizes
 286 and a delayed readout, rendering the protocol easier and more precise.

287

288 The eRRSA measures the difference in genomic content between treated and untreated malaria
 289 parasites at 120 h post perturbation, a full 48 h (or a full life cycle) after the RSA collections.
 290 Our results demonstrate that by allowing parasites an extra life cycle to recover, the differences
 291 between resistant and sensitive parasites are made even more drastic, suggesting the extra
 292 lifecycle for recovery helps further differentiate viable and nonviable parasites. With an extra life

cycle for recovery from drug treatment, the eRRSA measures recovery of the parasites, rather than the survivability of the parasites after treatment, and provides a more consistent readout compared to other publications (Additional file 5).

The demonstration of the effect of various setup conditions on the final outcome required an optimization of these parameters in the eRRSA. With no sorbitol synchronization required and only one single layer Percoll synchronization to select schizonts, parasites are synchronized easier, quicker, and closer to the ring-stage so that they can be set up in the assay sooner to avoid losing their synchronization. The variability in assay outcome caused by varying the delay between synchronization and treatment is likely due to the short window (0-3 h) that differentiates ART resistant parasites from ART sensitive parasites. The eRRSA assay is set up 6 h post-Percoll, which allows for a high percentage of early ring-stage, tightly synchronized parasites. Using flow cytometry for parasitemia measurements post-Percoll synchronization allows for rapid and accurate parasitemia determination and staging for many parasites at once at the set-up of the assay, which is an essential factor for the results of both RSA and eRRSA. Starting parasitemia has a substantial effect on growth throughout the assay; by using a lower starting parasitemia (0.5%) compared to the *in vitro* RSA, the eRRSA has a lower volume and parasitemia requirement while also allowing for more precise measurement of growth with and without drug treatment. Lower culture volume requirements permit the use of 96-well plates, which uses less reagents, time, and space.

Finally, it was demonstrated that the eRRSA shows superior correlation with the clinical phenotype $PC_{1/2}$. As ART resistance is currently presenting as a continuous phenotype, the ability to accurately determine intermediate phenotypes is critical in understanding ART resistance and identifying contributing genotypes beyond K13 propeller mutations. The efficacy and efficiency of the eRRSA makes it an excellent replacement for the traditional RSA in any study of ART resistance requiring accuracy and high-throughput.

The 15 cloned parasites examined include 3 which lack K13 mutations but show $PC_{1/2} > 5$. These include one clone (NHP4373) with $PC_{1/2} = 7.1$. Interestingly, these clones also show high eRRSA values, confirming their ART-R status. These results provide further support that ART-R may result from mutations elsewhere in the parasite genome, or perhaps from non-coding regulatory changes controlling K13 activity (17).

Conclusions

The eRRSA method described here provides a more robust *in vitro* representation of $PC_{1/2}$ while also providing vastly improved throughput. Widespread adaptation of the eRRSA should significantly accelerate our understanding of artemisinin resistance, allowing for both high throughput surveillance of the spread of resistance and for the precise phenotyping necessary to uncover complex genetic contributors to resistance.

List of abbreviations

RSA   Ring-stage survival assay

335	eRRSA	extended Recovery Ring-stage Survival Assay
336	DMSO	Dimethyl sulfoxide
337	ART	Artemisinin
338	ACTs	Artemisinin combination therapies
339	WHO	World Health Organization
340	PC _{1/2}	Patient clearance half-life
341	qPCR	quantitative Polymerase Chain Reaction
342	RBC	Red blood cell
343	CM	Complete media
344	PBS	Phosphate buffer saline
345	SYBR	SYBR Green I
346	SYTO	SYTO 61 red fluorescent nucleic acid stain
347	DHA	Dihydroartemisinin
348	Ct	cycle threshold
349	QTL	Quantitative trait loci

350

351 **Declarations**

352 **Ethics approval and consent to participate**

Ethical approval for the use of human blood in this study was granted by the Institutional Review Board of the University of Notre Dame. All of the blood used for the *in vitro* culturing of parasites was obtained from healthy adult volunteers and drawn by trained personnel from Interstate Blood Bank.

Consent for publication

Not applicable.

Availability of data and material

Data can be made available upon request to the corresponding author.

Competing interests

The authors declare that they have no competing interests.

Funding

Funding for this work was provided by NIH grant P01 AI127338 to MTF. SMRU is part of the Mahidol Oxford University Research Unit supported by the Wellcome Trust of Great Britain.

Authors' contributions

SZD, LAC, DAS, and MTF conceived and designed the experiments. PPS, LAC, DAS, GF, and MACs performed the experiments, analysed the data, and created figures. SZD, KMV, LAC, GF, and MTF wrote the manuscript. FHN, MMW and TJCA contributed materials/reagents/parasites. All authors read, edited, and approved the final manuscript.

Acknowledgements

We would like to acknowledge members of the Ferdig lab for helpful discussions.

References

1. Cerqueira GC, Cheeseman IH, Schaffner SF, Nair S, McDew-White M, Phyto AP, et al. Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. *Genome Biol.* 2017;18(1):78.
2. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. *Lancet Infect Dis.* 2017;17(5):491-7.
3. Das S, Saha B, Hati AK, Roy S. Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in Eastern India. *N Engl J Med.* 2018;379(20):1962-4.
4. Organization WH. World Malaria Report. Geneva, Switzerland: World Health Organization; 2018.
5. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. *Malar J.* 2011;10:339.
6. Group WKG-PS. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis. *BMC Med.* 2019;17(1):1.
7. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med.* 2014;371(5):411-23.
8. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. *Lancet Infect Dis.* 2013;13(12):1043-9.

- 393 9. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in
394 *Plasmodium falciparum* malaria. *N Engl J Med*. 2009;361(5):455-67.
- 395 10. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-
396 resistant *Plasmodium falciparum* in Pursat province, western Cambodia: a parasite clearance rate
397 study. *Lancet Infect Dis*. 2012;12(11):851-8.
- 398 11. Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, et al.
399 Altered temporal response of malaria parasites determines differential sensitivity to artemisinin.
400 *Proc Natl Acad Sci U S A*. 2013;110(13):5157-62.
- 401 12. Tirrell AR, Vendrely KM, Checkley LA, Davis SZ, McDew-White M, Cheeseman IH, et
402 al. Pairwise growth competitions identify relative fitness relationships among artemisinin
403 resistant *Plasmodium falciparum* field isolates. *Malar J*. 2019;18(1):295.
- 404 13. Kite WA, Melendez-Muniz VA, Moraes Barros RR, Wellems TE, Sá JM. Alternative
405 methods for the *Plasmodium falciparum* artemisinin ring-stage survival assay with increased
406 simplicity and parasite stage-specificity. *Malaria Journal*. 2016;15.
- 407 14. B Witkowski DM, C Amaratunga, RM Fairhurst. Ring - stage Survival Assays (RSA) to
408 evaluate the in - vitro and ex - vivo susceptibility of *Plasmodium falciparum* to artemisinins.
409 Institute Pasteur du Cambodge – National Institutes of
410 Health Procedure RSAv1.2013.
- 411 15. Lewis IA, Wacker M, Olszewski KL, Cobbold SA, Baska KS, Tan A, et al. Metabolic
412 QTL Analysis Links Chloroquine Resistance in *Plasmodium falciparum* to Impaired Hemoglobin
413 Catabolism. *PLoS Genetics*. 2014;10:e1004085.

- 414 16. Amaratunga C, Neal AT, Fairhurst RM. Flow cytometry-based analysis of artemisinin-
415 resistant *Plasmodium falciparum* in the ring-stage survival assay. *Antimicrob Agents Chemother*.
416 2014;58(8):4938-40.
- 417 17. Mukherjee A, Bopp S, Magistrado P, Wong W, Daniels R, Demas A, et al. Artemisinin
418 resistance without pfcykelch13 mutations in *Plasmodium falciparum* isolates from Cambodia.
419 *Malaria Journal*. 2017;16.
- 420 18. Cheeseman IH, McDew-White M, Phyto AP, Sriprawat K, Nosten F, Anderson TJ.
421 Pooled sequencing and rare variant association tests for identifying the determinants of emerging
422 drug resistance in malaria parasites. *Mol Biol Evol*. 2015;32(4):1080-90.
- 423 19. Phyto AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence
424 of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *The*
425 *Lancet*. 2012;379(9830):1960-6.
- 426 20. Dluzewski AR, Ling IT, Rangachari K, Bates PA, Wilson RJ. A simple method for
427 isolating viable mature parasites of *Plasmodium falciparum* from cultures. *Trans R Soc Trop*
428 *Med Hyg*. 1984;78(5):622-4.
- 429 21. Wacker MA, Turnbull LB, Walker LA, Mount MC, Ferdig MT. Quantification of
430 multiple infections of *Plasmodium falciparum* in vitro. *Malaria Journal*. 2012;11(1):180.
- 431 22. Wang Z, Cabrera M, Yang J, Yuan L, Gupta B, Liang X, et al. Genome-wide association
432 analysis identifies genetic loci associated with resistance to multiple antimalarials in *Plasmodium*
433 *falciparum* from China-Myanmar border. *Sci Rep*. 2016;6:33891.

23. Rovira-Graells N, Aguilera-Simon S, Tinto-Font E, Cortes A. New Assays to Characterise Growth-Related Phenotypes of *Plasmodium falciparum* Reveal Variation in Density-Dependent Growth Inhibition between Parasite Lines. *PLoS One*. 2016;11(10):e0165358.
24. Taylor AR, Schaffner SF, Cerqueira GC, Nkhoma SC, Anderson TJC, Sripawat K, et al. Quantifying connectivity between local *Plasmodium falciparum* malaria parasite populations using identity by descent. *PLoS Genet*. 2017;13(10):e1007065.
25. Anderson TJ, Nair S, McDew-White M, Cheeseman IH, Nkhoma S, Bilgic F, et al. Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites. *Mol Biol Evol*. 2017;34(1):131-44.

Tables and Figures

Table 1: Parasite isolates used in this study. Overview of 15 parasite isolates used in this study. Patient clearance rates were calculated with (5). Location of isolate collection and year of collection are as reported from Phyo et al. (19), Taylor et al. (24), and Cheeseman et al. (25). Samples were all collected from clinics on the northwestern border of Thailand. MKT = Mawker Thai, MLA = Maela, and WPA = Wang Pha.

Fig. 1. qPCR standard curve for detecting parasitemia of *P. falciparum* infected RBCs. A standard curve of samples ranging from 0.0001% parasitemia to 9% parasitemia were measured using qPCR amplification on the ABI 7900HT. Ct values were calculated based on three technical replicates using the ABI SDS 2.4.1. Ct value is inversely related to percent parasitemia

($R^2 = 0.9699$) and therefore can be used as a measurement of percent parasitemia in final RSA samples.

Fig. 2. Comparison of 72 h and 120 h perturbations. Parasites were set-up using the eRRSA protocol: 0.5% parasitemia at early ring stage and 700 nM DHA was applied and washed off after 6 h. Samples were collected at (A) 72 h post-drug treatment and at (B) 120 h post-drug treatment. Parasites are ordered from the smallest $PC_{1/2}$ (least resistant) to the largest $PC_{1/2}$ (most resistant) from left to right (with the sensitive control, 3D7 on the far left). Sensitive and resistant parasites were more distinguishable based on their 120 h post-drug treatment sample fold changes.

Fig. 3. 120 h eRRSA increases correlation with $PC_{1/2}$ compared to 72 h. (A) 15 isolates from Southeast Asia with varying $PC_{1/2}$ were assayed using the eRRSA. 72 h post-drug treatment samples were measured to give a fold change for each isolate and those fold changes were correlated with each isolate's $PC_{1/2}$ (Spearman $r = -0.6071$). Isolates with red boxes are *kelch13* mutants and the 95% confidence interval around the best-fit line is denoted with dotted lines. (B) The same 15 isolates were assayed using the eRRSA and 120 h post-drug treatment samples were measured to calculate a fold change for each isolate. The fold changes were correlated with $PC_{1/2}$ (isolates marked with red boxes are *kelch13* mutants and the 95% confidence interval of the best-fit line is denoted with dotted lines) (Spearman $r = -0.8393$); the 120 h eRRSA samples increased correlation with $PC_{1/2}$ compared to the 72 h samples.

Table 1. Parasite isolates used in this study.

Isolate	<i>kelch13</i> mutation	PC _{1/2}	Location	Year
NHP1333	N458I	9.24	MKT	2011
NHP1455	R561H	8.02	MKT	2012
NHP1337	C580Y	7.83	MKT	2011
NHP4333	C538V	7.7	WPA	2008
NHP4373	WT	7.1	WPA	2008
NHP3035	M476I	6.16	MLA	2008
NHP4078	A675V	5.82	WPA	2008
NHP4201	WT	5.65	WPA	2008
NHP4106	WT	5.54	WPA	2008
NHP4673	E252Q	5.34	WPA	2010
NHP4748	WT	2.89	WPA	2011
NHP4072	WT	2.29	WPA	2008
NHP3032	K438N	2.17	MLA	2008
NHP4302	WT	1.98	WPA	2008
NHP1386	WT	1.67	MKT	2011

Additional files

Additional File 1.pdf: Table of primer and cycling conditions used for quantitative PCR.

The forward and reverse primer sequences of the *Pfcr*t gene used in this study and the cycling conditions used in the fast mode of the ABI 7900HT.

Additional File 2.pdf: Effects of assay modification on final assay readout. (A) The starting parasitemia for the assay was set at 0.25%, 0.5%, or 1% (as measured by microscopy) for three different parasite isolates (3D7, 1337, and 4673) and the fold change between the treated (DHA) and untreated (DMSO) samples was measured with three biological replicates (each with three technical replicates) at 72 h post-drug treatment and (B) at 120 h post-drug treatment. After determining that a 0.25% parasitemia measured by microscopy was equivalent to 0.5% parasitemia measured by flow cytometry (C), the starting parasitemia was determined using flow cytometry and set to 0.5% and the time from Percoll synchronization to drug (DHA or DMSO) application was varied (4 h, 6 h 8 h, or 10 h) for the three different parasite isolates (3D7, 1337, and 4673) and the fold change between treated and untreated samples was measured with three biological replicates (each with three technical replicates) at 72 h post-drug treatment and (D) 120 h post-drug treatment.

Additional file 3.pdf. Comparison of microscopy vs flow cytometry to calculate starting parasitemia. Fold change data for two lines used as controls in eRRSA show little difference between a starting parasitemia of 0.25% by microscopy and a starting parasitemia of 0.5% determined by flow cytometry.

Additional File 4.pdf: Summary of modifications for the eRRSA compared to the standard RSA. A timeline comparing the various steps and the estimated time needed for each step of the standard WWARN RSA (14) (left) and the eRRSA (right). There are limiting steps in both the eRRSA and RSA (marked with orange arrows), but the eRRSA allows for more parasite isolates with more biological replicates to be done in less time compared to the standard RSA.

Additional file 5.pdf. Comparison of previously published correlation rates of RSA results with $PC_{1/2}$. Previous publications where $PC_{1/2}$ and RSA results on the same samples were

505 reported are listed here. If RSA results were available, then the Spearman correlation between
506 PC_{1/2} and RSA was calculated. If the Spearman correlation was not provided, it was internally
507 calculated and is marked with an *.

	Sequence
Forward	GGGTGATGTTGTAAGAGAACCA
Reverse	ACGAACAAGCCATTTGATATTACAC

Cycling conditions:
95° C 20 seconds
95° C 1 second
62.3 ° C 30 seconds
65° C 15 seconds

Fold Change

First Author	Year	Number of Isolates	RSA and PC1/2 Correlations	Journal	doi
Witkowski	2013	30	0.5476	Lancet Infect Dis.	10.1016/S1473-3099(13)70252-4
Amaratunga	2014	44	0.48511225	Antimicrobial Agents and Chemotherapy	10.1128/AAC.03055-14
Ariey	2014	49	NA	Nature	10.1038/nature12876
Wang	2015	182	NA	Antimicrobial Agents and Chemotherapy	10.1128/AAC.01255-15
Ye	2016	111	NA	Scientific Reports	10.1038/srep20100
Boullé	2016	25	NA	Emerg Infect Dis.	10.3201/eid2208.160004
Menard	2016	64	NA	Malaria Journal	10.1186/s12936-016-1622-x
Thanh	2017	9	NA	Malaria Journal	10.1186/s12936-017-1680-8
Mukherjee	2017	36	0.3534*	Malaria Journal	https://doi.org/10.1186/s12936-017-1845-5
Sá	2018	22	NA	PNAS	10.1073/pnas.1813386115
Das	2019	226	NA	Clinical Infectious Diseases	10.1093/cid/ciy1038
Phong	2019	25	NA	Malaria Journal	10.1186/s12936-019-2640-2